Lv11
35 积分 2021-02-22 加入
Identification of Or5v1/Olfr110 as an oxylipin receptor and anti-obesity target
1小时前
已完结
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
15天前
已完结
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
15天前
已完结
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
17天前
已完结
Next-generation immune cell engagers for B cell depletion in autoimmune diseases
1个月前
已完结
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
1个月前
已完结
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
1个月前
已完结
Systemic lupus erythematosus: Phase 2 trials to watch in 2026
1个月前
已关闭
Advances in the treatment of systemic lupus erythematosus
1个月前
已完结
Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B
2个月前
已完结
皖公网安备34019202002308
